Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Camrelizumab and Chemo for Gastric Cancer Conversion
NCT04889768Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04889768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889768.